Are intravitreal injections essential during the COVID-19 pandemic? Global preferred practice patterns and practical recommendations
Issued Date
2022-12-01
Resource Type
eISSN
20569920
Scopus ID
2-s2.0-85134023227
Journal Title
International Journal of Retina and Vitreous
Volume
8
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Retina and Vitreous Vol.8 No.1 (2022)
Suggested Citation
Tan A.C.S., Schwartz R., Anaya D., Chatziralli I., Yuan M., Cicinelli M.V., Faes L., Mustapha M., Phasukkijwatana N., Pohlmann D., Reynolds R., Rosenblatt A., Savastano A., Touhami S., Vaezi K., Ventura C.V., Vogt D., Ambati J., de Smet M.D., Loewenstein A. Are intravitreal injections essential during the COVID-19 pandemic? Global preferred practice patterns and practical recommendations. International Journal of Retina and Vitreous Vol.8 No.1 (2022). doi:10.1186/s40942-022-00380-6 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/85285
Title
Are intravitreal injections essential during the COVID-19 pandemic? Global preferred practice patterns and practical recommendations
Author's Affiliation
Siriraj Hospital
Bwrdd lechyd Prifysgol Aneurin Bevan
Berliner Institut für Gesundheitsforschung
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Kantonsspital Luzern
Università Cattolica del Sacro Cuore, Campus di Roma
University of Virginia School of Medicine
National and Kapodistrian University of Athens
Ludwig-Maximilians-Universität München
Singapore Eye Research Institute
IRCCS Ospedale San Raffaele
Sun Yat-Sen University
Universiteit Leiden
National University of Singapore
Moorfields Eye Hospital NHS Foundation Trust
The University of British Columbia
Università Vita-Salute San Raffaele
Singapore National Eye Centre
Tel Aviv University
Universiti Kebangsaan Malaysia
Sorbonne Université
Clínica de Oftalmología de Cali
Altino Ventura Foundation
MIOS sa
HOPE Eye Hospital
Bwrdd lechyd Prifysgol Aneurin Bevan
Berliner Institut für Gesundheitsforschung
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Kantonsspital Luzern
Università Cattolica del Sacro Cuore, Campus di Roma
University of Virginia School of Medicine
National and Kapodistrian University of Athens
Ludwig-Maximilians-Universität München
Singapore Eye Research Institute
IRCCS Ospedale San Raffaele
Sun Yat-Sen University
Universiteit Leiden
National University of Singapore
Moorfields Eye Hospital NHS Foundation Trust
The University of British Columbia
Università Vita-Salute San Raffaele
Singapore National Eye Centre
Tel Aviv University
Universiti Kebangsaan Malaysia
Sorbonne Université
Clínica de Oftalmología de Cali
Altino Ventura Foundation
MIOS sa
HOPE Eye Hospital
Other Contributor(s)
Abstract
Tertiary outpatient ophthalmology clinics are high-risk environments for COVID-19 transmission, especially retina clinics, where regular follow-up is needed for elderly patients with multiple comorbidities. Intravitreal injection therapy (IVT) for chronic macular diseases, is one of the most common procedures performed, associated with a significant burden of care because of the vigorous treatment regimen associated with multiple investigations. While minimizing the risk of COVID-19 infection transmission is a priority, this must be balanced against the continued provision of sight-saving ophthalmic care to patients at risk of permanent vision loss. This review aims to give evidence-based guidelines on managing IVT during the COVID-19 pandemic in common macular diseases such as age-related macular degeneration, diabetic macula edema and retinal vascular disease and to report on how the COVID-19 pandemic has affected IVT practices worldwide. To illustrate some real-world examples, 18 participants in the International Retina Collaborative, from 15 countries and across four continents, were surveyed regarding pre- and during- COVID-19 pandemic IVT practices in tertiary ophthalmic centers. The majority of centers reported a reduction in the number of appointments to reduce the risk of the spread of COVID-19 with varying changes to their IVT regimen to treat various macula diseases. Due to the constantly evolving nature of the COVID-19 pandemic, and the uncertainty about the normal resumption of health services, we suggest that new solutions for eye healthcare provision, like telemedicine, may be adopted in the future when we consider new long-term adaptations required to cope with the COVID-19 pandemic.
